Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Open Access
- 14 December 2023
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (50) , 2300261
Abstract
Background Shortly after the launch of a novel adjuvanted recombinant zoster vaccine (RZV), Shingrix, cases of suspected herpes zoster (HZ) or zoster-like skin reactions following immunisation were reported. Aim We aimed to investigate if these skin manifestations after administration of RZV could be HZ. Methods Between April and October 2020, general practitioners (GP) reporting a suspected case of HZ or zoster-like skin manifestation after RZV vaccination to the Paul-Ehrlich-Institut, the German national competent authority, were invited to participate in the study. The GP took a sample of the skin manifestation, photographed it and collected patient information on RZV vaccination and the suspected adverse event. We analysed all samples by PCR for varicella-zoster virus (VZV) and herpes-simplex virus (HSV) and genotyped VZV-positive samples. In addition, cases were independently assessed by two dermatologists. Results Eighty eligible cases were enrolled and 72 could be included in the analysis. Of the 72 cases, 45 were female, 33 were 60–69 years old, 32 had skin symptoms in the thoracic and 27 in the cervical dermatomes. Twenty-seven samples tested PCR positive for VZV (all genotyped as wild-type, WT), three for HSV-1 and five for HSV-2. Conclusion It may be difficult to distinguish HZ, without a PCR result, from other zoster-like manifestations. In this study, VZV-PCR positive dermatomal eruptions occurring in the first weeks after immunisation with RZV were due to WT VZV, which is not unexpected as HZ is a common disease against which the vaccine is unlikely to provide full protection at this time.Keywords
This publication has 23 references indexed in Scilit:
- Herpes zoster and the search for an effective vaccineClinical and Experimental Immunology, 2016
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled studyVaccine, 2014
- Herpes ZosterNew England Journal of Medicine, 2013
- Sampling of herpes zoster skin lesion types and the impact on viral DNA detectionJournal of Virological Methods, 2013
- Should Varicella-Zoster Virus Culture Be Eliminated? A Comparison of Direct Immunofluorescence Antigen Detection, Culture, and PCR, with a Historical ReviewJournal of Clinical Microbiology, 2012
- Herpes zoster in Germany: Quantifying the burden of diseaseBMC Infectious Diseases, 2011
- Aging, Immunity, and the Varicella–Zoster VirusNew England Journal of Medicine, 2005
- Genetic Profile of an Oka Varicella Vaccine Virus Variant Isolated from an Infant with ZosterJournal of Clinical Microbiology, 2004
- Rapid Detection of Herpes Simplex Virus and Varicella-Zoster Virus Infections by Real-Time PCRJournal of Clinical Microbiology, 2003